AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study

ABSTRACT AFQ056 is a novel, selective metabotropic glutamate receptor 5 antagonist. This was a 13‐week, double‐blind, placebo‐controlled study. Patients with Parkinson's disease and moderate‐to‐severe levodopa (l‐dopa)‐induced dyskinesia who were receiving stable l‐dopa/anti‐parkinsonian treatm...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Movement disorders 2013-11, Vol.28 (13), p.1838-1846
Hauptverfasser:	Stocchi, Fabrizio, Rascol, Olivier, Destee, Alain, Hattori, Nobutaka, Hauser, Robert A., Lang, Anthony E., Poewe, Werner, Stacy, Mark, Tolosa, Eduardo, Gao, Haitao, Nagel, Jennifer, Merschhemke, Martin, Graf, Ana, Kenney, Christopher, Trenkwalder, Claudia
Format:	Artikel
Sprache:	eng
Schlagworte:	AFQ056 Aged Antiparkinson Agents - adverse effects Antiparkinson Agents - therapeutic use Cognition Disorders - drug therapy Cognition Disorders - etiology Dose-Response Relationship, Drug Double-Blind Method Dyskinesia, Drug-Induced - drug therapy Dyskinesia, Drug-Induced - etiology dyskinesias Female Follow-Up Studies glutamate antagonists Humans Indoles - therapeutic use International Cooperation levodopa (l-dopa) Levodopa - adverse effects Male Middle Aged Movement disorders Outcome Assessment (Health Care) Parkinson Disease - complications Parkinson Disease - drug therapy Parkinson's disease Psychiatric Status Rating Scales Severity of Illness Index Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!